PMID- 34079375
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression 
      Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
PG  - 4233-4240
LID - 10.2147/CMAR.S304820 [doi]
AB  - OBJECTIVE: Compared the outcomes between lenvatinib plus camrelizumab therapy and 
      lenvatinib monotherapy as post-progression treatment for advanced hepatocellular 
      carcinoma (HCC) with progressive disease (PD). PATIENTS AND METHODS: A total of 
      48 advanced HCC patients were included in this retrospective study between June 
      2019 and March 2020. The patients were divided into the lenvatinib plus 
      camrelizumab group (n=21) and the lenvatinib group (n=27). Primary endpoints were 
      overall survival (OS) and progression-free survival (PFS), and secondary 
      endpoints were the objective response rate (ORR) and adverse events (AEs). 
      RESULTS: The median follow-up time was 8.4 months. The median OS was not 
      obtained. The median PFS of lenvatinib plus camrelizumab group was significantly 
      longer than that of lenvatinib group (8.0 months vs 4.0 months, p=0.011). 
      Compared with lenvatinib group, lenvatinib plus camrelizumab group had higher ORR 
      (28.57% vs 7.41%) and disease control rate (DCR) (71.43% vs 51.85%). The most 
      common adverse events (AEs) included hand-foot skin reaction, hypertensions and 
      abnormal hepatic function damage. Overall, 23.81% and 25.93% of patients 
      experienced grade >/=3AEs in the lenvatinib plus camrelizumab group and the 
      lenvatinib group, respectively. CONCLUSION: Lenvatinib plus camrelizumab as 
      post-progression treatment is effective and safe for advanced hepatocellular 
      carcinoma with PD.
CI  - (c) 2021 Wei et al.
FAU - Wei, Fuqun
AU  - Wei F
AD  - Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of 
      Fujian Medical University, Fuzhou, 350025, People's Republic of China.
FAU - Huang, Qizhen
AU  - Huang Q
AD  - Department of Radiation Oncology, Mengchao Hepatobiliary Hospital of Fujian 
      Medical University, Fuzhou, 350025, People's Republic of China.
FAU - He, Jian
AU  - He J
AD  - Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of 
      Fujian Medical University, Fuzhou, 350025, People's Republic of China.
FAU - Luo, Liuping
AU  - Luo L
AD  - Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of 
      Fujian Medical University, Fuzhou, 350025, People's Republic of China.
FAU - Zeng, Yongyi
AU  - Zeng Y
AD  - Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of 
      Fujian Medical University, Fuzhou, 350025, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210527
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC8166816
OTO - NOTNLM
OT  - PD-1
OT  - advanced hepatocellular carcinoma
OT  - lenvatinib
COIS- The authors declare that they have no competing interests.
EDAT- 2021/06/04 06:00
MHDA- 2021/06/04 06:01
PMCR- 2021/05/27
CRDT- 2021/06/03 06:38
PHST- 2021/02/05 00:00 [received]
PHST- 2021/05/10 00:00 [accepted]
PHST- 2021/06/03 06:38 [entrez]
PHST- 2021/06/04 06:00 [pubmed]
PHST- 2021/06/04 06:01 [medline]
PHST- 2021/05/27 00:00 [pmc-release]
AID - 304820 [pii]
AID - 10.2147/CMAR.S304820 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 May 27;13:4233-4240. doi: 10.2147/CMAR.S304820. 
      eCollection 2021.